subjects in each group ( 22 copd and 53 asthma ) were randomly assigned to treatment with three puffs of metaproterenol ( 0.65 mg/puff ) via the mdi with inspirease plus nebulizer with placebo , or placebo mdi with inspirease plus nebulizer with 15 mg metaproterenol in double blind fashion .
C0004096
asthma
C0029193
double blind